Skip to content

Clinical trials

Completed Phase 1 Lymphoma, Non-Hodgkin trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Lymphoma, Non-Hodgkin Phase: Phase 1 Status: Completed Clear all

371 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
200013
20018
200213
200310
200418
200511
200618
200725
200818
200917
201014
201119
201215
201318
201410
201512
201611
201717
201815
20199
202013
20218
20224
20234
20261

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed371

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Cancer Institute (NCI)52
Memorial Sloan Kettering Cancer Center11
M.D. Anderson Cancer Center10
National Institutes of Health Clinical Center (CC)9
AbbVie8
Case Comprehensive Cancer Center8
Genentech, Inc.7
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins7
Celgene6
GlaxoSmithKline6

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Lymphoma, Non-Hodgkin371
Leukemia, Lymphocytic, Chronic, B-Cell177
Lymphoma, Follicular163
Lymphoma, Large B-Cell, Diffuse156
Hodgkin Disease154
Precursor Cell Lymphoblastic Leukemia-Lymphoma153
Lymphoma, Mantle-Cell149
Lymphoma142
Lymphoma, B-Cell, Marginal Zone136
Burkitt Lymphoma131

Trials

Showing 1 to 25 of 371. Each trial links to its page on Pharma Observatory.

271 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.